The aim of the present prospective study is to evaluate the clinical consequences of the last ESPGHAN and BSPGHAN guidelines for the diagnosis of Coeliac Disease (CD). All children (aged 0-18 years) diagnosed with CD from January 2011 to May 2014 at the IRCCS Burlo Garofolo of Trieste (Italy) were prospectively enrolled. Children diagnosed without a duodenal biopsy (Group 1) were matched for sex, age, and year of diagnosis to a sample of children diagnosed with a duodenal biopsy (Group 2). All patients were put on Gluten Free Diet (GFD) and followed-up for clinical condition, BMI, and laboratory tests (haemoglobin, serum anti-transglutaminase IgA antibodies) at six months and every year since diagnosis (median follow-up: 1.9 years). Adherence to GFD and quality of life of children were assessed through validated questionnaires. 51 out of 468 (11%) patients were diagnosed without a duodenal biopsy (Group 1; median age 2.1 years) and matched to 92 patients diagnosed with a biopsy (Group 2; median age 2.4 years). At the end of the follow-up the two groups resulted statistically comparable for clinical and nutritional status, serum anti-transglutaminase IgA antibodies titres, quality of life, adherence to GFD, and number of supplementary post-diagnosis medical consultations. The diagnosis of CD can be safely performed without a duodenal biopsy at least in 11% of cases. At least during a medium-term follow-up, this approach has no negative consequence on clinical remission, adherence to diet, and quality of children's lives.
|Translated title of the contribution||Diagnosis of coeliac disease without biopsy: From theory to practice|
|Number of pages||6|
|Journal||Medico e Bambino|
|Publication status||Published - Mar 1 2016|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health